JP2019522037A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522037A5
JP2019522037A5 JP2019504916A JP2019504916A JP2019522037A5 JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5 JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5
Authority
JP
Japan
Prior art keywords
hours
hour
vivo
cell
adjusted according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019504916A
Other languages
English (en)
Japanese (ja)
Other versions
JP6885629B2 (ja
JP2019522037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/043979 external-priority patent/WO2018022771A1/en
Publication of JP2019522037A publication Critical patent/JP2019522037A/ja
Publication of JP2019522037A5 publication Critical patent/JP2019522037A5/ja
Priority to JP2021078313A priority Critical patent/JP7208659B2/ja
Application granted granted Critical
Publication of JP6885629B2 publication Critical patent/JP6885629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019504916A 2016-07-29 2017-07-26 インドリノン化合物の使用 Active JP6885629B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078313A JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662368707P 2016-07-29 2016-07-29
US62/368,707 2016-07-29
US201662417572P 2016-11-04 2016-11-04
US62/417,572 2016-11-04
US201662422504P 2016-11-15 2016-11-15
US62/422,504 2016-11-15
US201662426107P 2016-11-23 2016-11-23
US62/426,107 2016-11-23
US201762503238P 2017-05-08 2017-05-08
US62/503,238 2017-05-08
US201762534067P 2017-07-18 2017-07-18
US62/534,067 2017-07-18
PCT/US2017/043979 WO2018022771A1 (en) 2016-07-29 2017-07-26 Uses of indolinone compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020204766A Division JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Division JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Publications (3)

Publication Number Publication Date
JP2019522037A JP2019522037A (ja) 2019-08-08
JP2019522037A5 true JP2019522037A5 (https=) 2019-10-17
JP6885629B2 JP6885629B2 (ja) 2021-06-16

Family

ID=61011754

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504916A Active JP6885629B2 (ja) 2016-07-29 2017-07-26 インドリノン化合物の使用
JP2020204766A Active JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Active JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020204766A Active JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Active JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Country Status (11)

Country Link
US (4) US10159660B2 (https=)
EP (1) EP3490553B1 (https=)
JP (3) JP6885629B2 (https=)
KR (2) KR102282794B1 (https=)
CN (2) CN109789127B (https=)
CA (1) CA3029851A1 (https=)
MX (1) MX395539B (https=)
PH (1) PH12019500070A1 (https=)
SG (1) SG11201811661TA (https=)
TW (2) TWI857351B (https=)
WO (1) WO2018022771A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204376B1 (en) * 2014-10-09 2023-04-19 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) * 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
WO2020113216A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
US20240139153A1 (en) * 2020-09-17 2024-05-02 Oklahoma Medical Research Foundation Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression
WO2022266491A1 (en) * 2021-06-18 2022-12-22 University Of Maryland, Baltimore Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
US12447163B2 (en) * 2021-07-16 2025-10-21 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of Bcl inhibitors
WO2025137592A2 (en) * 2023-12-21 2025-06-26 Anuj Bellare Diazirine monomers and polymer compositions derived therefrom
WO2025235561A1 (en) * 2024-05-08 2025-11-13 Enspire Group LLC Venetoclax oral drugs and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
DE69922997T2 (de) 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
EP1259514B9 (en) 2000-02-28 2005-11-09 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CA2953987A1 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
HRP20131103T1 (hr) 2007-04-20 2013-12-20 The Research Foundation Of State University Of New York Benzimidazoli i njihovi farmaceutski pripravci
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
CA2869513C (en) * 2012-04-12 2020-07-07 Georgetown University Methods and compositions for treating ewings sarcoma family of tumors
WO2014015153A2 (en) 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
US9393232B2 (en) * 2013-04-26 2016-07-19 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
KR101500363B1 (ko) * 2013-07-01 2015-03-16 현대자동차 주식회사 하이브리드 자동차의 동력전달장치
JP2016529246A (ja) * 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
CN105848654B (zh) 2013-10-24 2018-10-02 乔治城大学 用于治疗癌症的方法和组合物
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20160022684A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
US20170281642A1 (en) * 2014-08-28 2017-10-05 Oncoethix Gmbh Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds
EP3204376B1 (en) 2014-10-09 2023-04-19 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
US20190255127A1 (en) 2018-02-21 2019-08-22 Batu Biologics, Inc. Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells

Similar Documents

Publication Publication Date Title
JP2019522037A5 (https=)
Janiszewski et al. Content and process priming: A review
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2024010140A (es) Nuevos metodos.
WO2015095624A3 (en) Drug mixing and delivery system and method
WO2017091749A8 (en) Shape changing drug delivery devices and methods
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
JP2015057451A5 (https=)
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MX2016006318A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX375241B (es) Métodos y herramientas relacionadas con la administración de medio de contraste.
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
HK1255481A1 (zh) 用於治疗hcv的方法
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
MX337850B (es) Lipoatrofia cosmetica medicinal.
NZ712584A (en) Antitumor agent including irinotecan hydrochloride hydrate
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito
ME02839B (me) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
Rojas et al. Ultrasound and ethanol pre-treatments to improve drying and rehydration of pumpkin
UA117105U (uk) Спосіб застосування препарату xyla для анестезії плідників осетрових в процесі штучного відтворення
HK1214511A1 (zh) 盐酸兰地洛尔在快速性心律失常的长期治疗中的用途